In_vitro_response_of_a_human_colon_tumor_xenograft_and_a_lung_adenocarcinoma_cell_line_to_alpha-difluoromethylornithine_alone_and_in_combination_with_5-fluorouracil_and_doxorubicin._We_have_investigated_effects_of_alpha-difluoromethylornithine_(DFMO),_both_as_a_single_agent_and_in_combination_with_5-fluorouracil_(5-FU)_against_a_human_colon_tumor_xenograft_(T6)_grown_as_primary_tissue_culture_in_serum-free_medium_and_in_combination_with_doxorubicin_(DX)_against_a_human_lung_adenocarcinoma_cell_line_(A549)._DFMO_showed_a_dose-dependent_growth-inhibitory_effect_against_human_colon_tumor_xenograft_and_lung_adenocarcinoma_cells._Growth-inhibitory_activity_of_DFMO_against_T6_cells_was_reversed_completely_when_the_cells_were_treated_simultaneously_with_putrescine_(PU)_(10(-6)_M)_and_DFMO_(10(-3)_M)._When_5-FU_and_DFMO_were_used_in_combination_against_T6_cells,_no_antagonism_or_synergism_between_the_two_drugs_was_seen._However,_in_the_case_of_A549_cells,_when_DFMO_was_used_in_combination_with_DX,_there_was_a_consistent_increase_in_growth_inhibition_that_surpassed_the_inhibition_of_either_agent_given_alone.